Skip to main content
. 2018 Jan 11;7:1. doi: 10.1186/s40164-018-0093-x

Table 2.

Summary of adverse effects on the trial

Adverse events Total, n (%) Grade 1 and 2 Grade 3 Grade 4 Grade 5
Related to WT1 vaccine (all with Montanide)
 Injection sites ulceration 1 (14%) 1
 Injection sites reaction 4 (57%) 4
SAEs unrelated to WT1 vaccine
 Ascending myelitis due to infection 1 (14%) 1
 Hyperglycemia due to uncontrolled DM 1 (14%) 1
 Thrombocytopenia due to disease 1 (14%) 1
 Anemia due to disease 1 (14%) 1
 Depression 1 (14%) 1
 Upper respiratory infection (viral) 3 (43%) 3